Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Project funding for personalised childhood cancer treatments

MRC MHU Paediatrics

Funding from the Azaylia Foundation will support the Scientific Advances for Infant Leukaemia (SAIL) programme.

An adult holds a baby's hand in theirs. © Hu Chen/Unsplash

Yesterday it was announced that the Azaylia Foundation have donated £101,850 to fund the Scientific Advances for Infant Leukaemia (SAIL) programme, a UK-wide collaboration between the University of Oxford's Department of Paediatrics and Great Ormond Street Hospital.

The programme prioritises the development of treatments tailored to childhood cancers. Researchers in the programme, including the Childhood Leukaemia Research Group from the MRC WIMM and MRC MHU, aim to create a roadmap for all types of leukaemia, and improve prognosis for patients with cancers such as acute lymphoblastic leukaemia (ALL).

Tell us your news

Paper accepted?

Received an award?

Contact communications@imm.ox.ac.uk to feature your story.

Similar stories